Holen Sie sich die Stockscreener-App
1.22
2.40%
-0.03
Handel nachbörslich:
1.22
Schlusskurs vom Vortag:
$1.25
Offen:
$1.23
24-Stunden-Volumen:
312.65K
Relative Volume:
0.36
Marktkapitalisierung:
$228.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$52.50M
KGV:
41.92
EPS:
0.0291
Netto-Cashflow:
$-4.13M
1W Leistung:
+3.39%
1M Leistung:
-5.43%
6M Leistung:
+18.45%
1J Leistung:
+66.67%
1-Tages-Spanne:
$1.20
$1.24
1-Wochen-Bereich:
$1.14
$1.28
52-Wochen-Spanne:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Firmenname
Tevogen Bio Holdings Inc
Sektor
Branche
Telefon
646-807-8832
Adresse
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Vergleichen Sie TVGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.22 | 228.03M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Eingeleitet | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Sees Large Growth in Short Interest - Defense World
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target DiscoveryRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Tevogen Uses AI To Advance EBV-Specific T Cell Therapy Toward Clinical Trials - Nasdaq
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered - Bluefield Daily Telegraph
Breakthrough: AI Technology Accelerates EBV Cancer Treatment Discovery at Tevogen - Stock Titan
Tevogen Bio (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital - Defense World
Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives - Nasdaq
Tevogen expands headquarters in Warren, New Jersey - Yahoo Finance
Tevogen’s lease agreement will double headquarters footprint at Warren HQ - ROI-NJ
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives - The National Law Review
Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft - Nasdaq
Tevogen Transforms into AI Powerhouse: $36B Revenue Target as Company Doubles HQ Size - Stock Titan
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Shares Purchased by Northern Trust Corp - Defense World
tevogen bio expands office lease in new jersey with key amendment - Investing.com Canada
Tevogen Bio Expands Office Space in New Jersey - TipRanks
Tevogen Bio expands AI in immunotherapy development By Investing.com - Investing.com South Africa
Tevogen Bio expands AI in immunotherapy development - Investing.com India
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships - The Manila Times
Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies - Nasdaq
Tevogen Details its Artificial Intelligence Initiative, - GlobeNewswire
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered ... - Bluefield Daily Telegraph
Tevogen Teams Up with Microsoft to Transform Healthcare: New AI Platform Targets $5T Industry - Stock Titan
Tariff Twist and PCE Ahead—Markets Hold Key Support - The Globe and Mail
This Raytheon Rival Is on Track to Hit New 52-Week Highs - The Globe and Mail
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla - The Globe and Mail
Is IonQ Stock a Buy Now? - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Sees Large Drop in Short Interest - Defense World
4 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - Insider Monkey
Tevogen expands target for COVID treatment to seniors By Investing.com - Investing.com India
Tevogen expands target for COVID treatment to seniors - Investing.com Australia
Tevogen Bio Plans to Expand Specialty Care Pipeline to - GlobeNewswire
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow - The Globe and Mail
Tevogen to Update on Robust Portfolio Assets, Business - GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting - The Manila Times
Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025 - Nasdaq
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited ... - Bluefield Daily Telegraph
Tevogen Unveils Massive $10B Portfolio Valuation and AI Expansion Ahead of Critical June Meeting - Stock Titan
Nvidia-Foxconn AI Alliance Could Disrupt the Supercomputer Market—What’s at Stake for Investors - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock Position Raised by Barclays PLC - Defense World
Tevogen Bio Holdings Inc. SEC 10-Q Report - TradingView
Tevogen Bio (NASDAQ:TVGN) Given “Buy” Rating at D. Boral Capital - Defense World
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - The Manila Times
Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition - Nasdaq
JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World
Finanzdaten der Tevogen Bio Holdings Inc-Aktie (TVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):